ClinicalTrials.gg
CompletedNCT06020014AJAXUpdated Nov 13, 2025

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

A Phase 2 interventional study of AZD4604 and Placebo in Asthma, sponsored by AstraZeneca. Completed at 124 sites in 18 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
339
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
95th of 248
339 · median 175
Started
2023
with 9 others
Phase 2
50 of 359
2 open now
Registered
307th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 95th largest by enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2023, is one of 50 in phase 2, and was the 307th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma, Janus kinase inhibitor
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 80 years of age inclusive, at the time of signing the .
  2. Treated with medium-high dose ICS in combination with LABA at a stable dose for at least 28 days prior to Visit 1.

    Note: EU participants must be treated with high dose ICS in combination with LABA at a stable dose for at least 28 days prior to V1.

  3. Documented history of ≥ 1 severe asthma exacerbation within 1 year prior to Visit 1.
  4. Morning pre-BD ≥ 40% predicted at Visit 1 and Visit 3.
  5. Able to perform acceptable lung function testing for FEV1 according to ATS/ERS 2019 acceptability criteria.
  6. Documented evidence of asthma in the 10 years up to or including Visit 1. A clinical diagnosis of asthma must be documented at least 12 months prior to Screening (Visit 1).
  7. An ACQ-6 score ≥ 1.5 at Visit 1 and at Visit 3.

9. Body weight of ≥ 40 kg and of \< 35 kg/m2. 10. use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. There are no restrictions on male participants or their female partners

At the end of the Run-in period (Visit 3), participants must fulfil the following additional criteria in order to be randomised into the study and enter the Treatment period:

  1. Pre-BD FEV1 ≥ 40%.
  2. A pre-BD/pre-IMP dose FEV1 at Visit 3 that has not increased or decreased by 20% or more from the pre-BD FEV1 recorded at Visit 1 and at Visit 2.
  3. An ACQ-6 score of ≥ 1.5.
  4. At least 80% compliance with usual asthma background medication during Run-in period (from Visit 2 to Visit 3) based on the daily asthma ePROs.
  5. Minimum 80% compliance with daily eCOAs (electronic Clinical Outcome Assessments) during the 14 days preceding Visit 3.
  6. For female of child bearing potential participants, a negative urine pregnancy test prior to administration of IMP.

Exclusion criteria

Exclusion Criteria:

  1. A severe asthma exacerbation within 8 weeks prior to randomisation.
  2. History of herpes zoster reactivation.
  3. Participants with a significant COVID-19 illness within 6 months of enrolment.
  4. pulmonary disease other than asthma.
  5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

    • affect the safety of the participant throughout the study,
    • influence the findings of the study or the interpretation, or
    • impede the participant's ability to complete the entire duration of study.
  6. Any clinically significant cardiac or cerebrovascular disease.
  7. History of venous thromboembolism.
  8. Participants who, as judged by the investigator, have evidence of active TB, or latent TB without completion of an appropriate course of treatment or appropriate ongoing prophylactic treatment.
  9. Participants with a recent history of, or who have a positive test for, infective hepatitis or unexplained jaundice, or participants who have been treated for .
  10. Current or prior history of alcohol or drug abuse (including marijuana and marijuana containing valid prescriptions), as judged by the investigator.
  11. History of other than superficial basal cell carcinoma.
  12. Treatment with systemic within 4 weeks (oral) or 8 weeks (intramuscular) before Visit 1.
  13. Any therapy within 12 weeks prior to Visit 1.
  14. Treatment with marketed biologics within 6 months of Visit 1 or 5 half-lives, whichever is longer.
  15. Inhaled corticosteroid plus fast-acting β2 agonist as a reliever is not allowed 15 days prior to Visit 1, during Screening/Run-in and throughout the Treatment period and preferably 1 week after the last dose of IMP.
  16. Live, attenuated, or mRNA vaccines within 4 weeks of Visit 1.
  17. Immunoglobulin or blood products within 4 weeks of Visit 1.
  18. Any immunotherapy within 6 months of Visit 1, except for stable maintenance dose allergen-specific immunotherapy started at least 4 weeks prior to Visit 1 and expected to continue through to the end of the Follow-up period.
  19. Concurrent enrolment in another interventional clinical study
  20. Participant treated with any drug within 4 months or 5 half-lives, whichever is longer, prior to Visit 1.
  21. Participants with a known to AZD4604 or any of the of the product.
  22. Abnormal findings identified on physical examination, , or laboratory testing.
  23. For female participants only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
  24. Current smokers or participants with smoking history ≥ 10 pack-years.
  25. Participants with a known long-term exposure to occupational asbestos, silica, radon, heavy metals, and polycyclic aromatic hydrocarbons.
  26. Positive family history of primary lung cancer in first degree relatives (mother, father, sisters, brothers and children).
  27. Positive urine cotinine test or exhaled carbon monoxide test at Visit 1 and at any timepoint throughout the study.
  28. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  29. Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  30. Donation of blood (≥ 450 mL) within 3 months or donation of plasma within 14 days before Visit 1.
  31. Major surgery within 8 weeks prior to Visit 1, or planned inpatient surgery, major dental procedure or hospitalisation during Screening, Treatment, or Follow-up periods.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
339 participants (actual)

Study arms

  • Experimental
    Arm 1

    AZD4604

    Drug: AZD4604

  • Placebo comparator
    Arm 2

    Placebo

    Other: Placebo

Interventions

  • AZD4604

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Time to first CompEx Asthma event

    CompEx Asthma is a composite surrogate endpoint for exacerbations that captures: - acute worsening events based on a combination of events based on ePRO data (asthma symptoms and rescue medication use), PEF data, and severe asthma exacerbation events.

    Time frame: 12 weeks

Secondary outcomes

  1. Pre-BD FEV1

    Change from baseline in pre-bronchodilator forced expiratory volume in 1 second.

    Time frame: 12 weeks

  2. CAAT

    Change from baseline in the Chronic Airways Assessment Test (CAAT). The CAAT is an 8-item patient-reported outcome measure developed to measure health status in patients with asthma and COPD.

    Time frame: 12 weeks

  3. ACQ-6

    Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6). The ACQ-6 has 6 questions (regarding asthma symptoms and rescue bronchodilator use). Answering the questions results in a score out of 6. A Score of 0 indicates complete control and 6 reflects severely uncontrolled disease.

    Time frame: 12 weeks

  4. Average morning and average evening PEF

    Change from baseline in 2-weekly average morning and evening Peak Expiratory Flow (PEF).

    Time frame: 12 weeks

  5. Daily asthma symptom score (total, daytime, and night-time)

    Change from baseline in 2-weekly average Daily asthma symptom score. Asthma symptoms are assessed (0 to 3 scale) twice daily, once in the morning and once in the evening.

    Time frame: 12 weeks

  6. Time to first CompEx acute worsening event

    Time to first CompEx Asthma acute worsening event.

    Time frame: 12 weeks

  7. CompEx event rate

    The number of CompEx Asthma events recorded in the 12-week period.

    Time frame: 12 weeks

  8. CompEx acute worsening event rate

    The number of CompEx Asthma acute worsening events recorded in the 12-week period.

    Time frame: 12 weeks

  9. FeNO

    Change from baseline in FeNO at Week 4 and Week 12.

    Time frame: 12 weeks

  10. Cough

    Change from baseline in cough severity at Week 4 and Week 12. This will be measured by Cough Severity Item Visual Analogue Scale, a 100-point linear scale marked with a horizontal or vertical line by the participant between the 2 extremes. Zero represents no cough while 100 represents worst cough imaginable.

    Time frame: 12 weeks

  11. PK

    AZD4604 plasma concentration pre- and post-dose at Week 4, pre-dose at Week 12.

    Time frame: 12 weeks

07

Study locations

124 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    Lakeland, Florida 33813, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Atlanta, Georgia 30344, United States
  • Research Site
    Hammond, Indiana 46324, United States
  • Research Site
    New Bedford, Massachusetts 02740, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Southfield, Michigan 48075, United States
  • Research Site
    Saint Charles, Missouri 63301, United States
  • Research Site
    Las Vegas, Nevada 89106, United States
  • Research Site
    Union City, New Jersey 07087, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Salisbury, North Carolina 28144, United States
  • Research Site
    Winston-Salem, North Carolina 27104, United States
  • Research Site
    Columbus, Ohio 43207, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Buenos Aires, C1012AAR, Argentina
  • Research Site
    Buenos Aires, C1425BEN, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1425, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1414AIF, Argentina
  • Research Site
    Florida, B1602DQD, Argentina
  • Research Site
    La Plata, B1900AVG, Argentina
  • Research Site
    Ranelagh, 1886, Argentina
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Blumenau, 89030-101, Brazil
  • Research Site
    Campinas, 13060-080, Brazil
  • Research Site
    Campinas, 13060-904, Brazil
  • Research Site
    Porto Alegre, 90035074, Brazil
  • Research Site
    Porto Alegre, 90160-093, Brazil
  • Research Site
    São Bernardo do Campo, 09715090, Brazil
  • Research Site
    São Bernardo do Campo, 09750-420, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    Pazardzhik, 4400, Bulgaria
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Aarhus, 8200, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    København NV, 2400, Denmark
  • Research Site
    København Ø, 2100, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Lyon, 69317, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Berlin, 10367, Germany
  • Research Site
    Berlin, 12159, Germany
  • Research Site
    Berlin, 12203, Germany
  • Research Site
    Berlin, 13187, Germany
  • Research Site
    Cottbus, 03050, Germany
  • Research Site
    Frankfurt am Main, 60596, Germany
  • Research Site
    Koblenz, 56068, Germany
  • Research Site
    Mainz, 55128, Germany
  • Research Site
    Peine, 31224, Germany
  • Research Site
    Ajmer, 305001, India
  • Research Site
    Belagavi, 590010, India
  • Research Site
    Coimbatore, 641028, India
  • Research Site
    Hyderabad, 500068, India
  • Research Site
    Kolkata, 700014, India
  • Research Site
    Kozhikode, 673008, India
  • Research Site
    New Delhi, 110029, India
  • Research Site
    Kajang, 43000, Malaysia
  • Research Site
    Kota Bharu, 15586, Malaysia
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuantan, 25100, Malaysia
  • Research Site
    Malacca, 75400, Malaysia
  • Research Site
    Sarawak Miri, 98000, Malaysia
  • Research Site
    Sungai Buloh, 47000, Malaysia
  • Research Site
    Dagupan, 2400, Philippines
  • Research Site
    Davao City, PH-8000, Philippines
  • Research Site
    Mabalacat, 2023, Philippines
  • Research Site
    Manadaluyong City, 1552, Philippines
  • Research Site
    Quezon City, 0870, Philippines
  • Research Site
    Roxas City, 5800, Philippines
  • Research Site
    Cape Town, 7764, South Africa
  • Research Site
    Durban, 4001, South Africa
  • Research Site
    Durban, 4091, South Africa
  • Research Site
    eMkhomazi, 4170, South Africa
  • Research Site
    Newton, 2113, South Africa
  • Research Site
    Observatory, 7925, South Africa
  • Research Site
    Daegu, 42415, South Korea
  • Research Site
    Gyeonggi-do, 13620, South Korea
  • Research Site
    Incheon, 21565, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 04763, South Korea
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Majadahonda, 28222, Spain
  • Research Site
    Palma de Mallorca, 07010, Spain
  • Research Site
    Linköping, 587 58, Sweden
  • Research Site
    Lund, 22185, Sweden
  • Research Site
    Örebro, 70185, Sweden
  • Research Site
    Kaohsiung City, 80756, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    Taipei, 10449, Taiwan
  • Research Site
    Taipei, 110, Taiwan
  • Research Site
    Taipei, 112, Taiwan

Showing the first 100 of 124 sites across 18 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Oct 2025, 23 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Aug 31, 2023
StartActual
Nov 16, 2023
Primary completionActual
Oct 28, 2025
CompletionActual
Oct 28, 2025
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06020014
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 31, 2023
Start date
Nov 16, 2023
Primary completion
Oct 28, 2025
Completion
Oct 28, 2025
Last update
Nov 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Londamocitinib

Start the discussion